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Abstract: Objective: To assess the differences in the pharmacokinetic profiles of S-ketamine, R-ketamine
and their metabolites, S-norketamine and R-norketamine, and to measure relevant physiologic variables
after intravenous administration of racemic (RS) ketamine or S-ketamine alone in Beagle dogs sedated
with medetomidine. Study design: Experimental, blinded and randomized crossover study. Animals: A
total of six (three female and three male) adult Beagle dogs. Methods: Medetomidine (450 ฀g m–2) was
administered intramuscularly, followed by either S-ketamine (2 mg kg–1) or RS-ketamine (4 mg kg–1)
20 minutes later, both administered intravenously. Blood samples were collected before medetomidine
administration and at multiple time points 1–900 minutes following the ketamine administration. Plasma
samples were analysed using liquid chromatography–tandem mass spectrometry. Heart rate, respiratory
rate, noninvasive blood pressure, haemoglobin saturation with oxygen and body temperature were mea-
sured at baseline, before ketamine administration, and 1, 2, 5, 10, 15, 20 and 30 minutes after ketamine
administration. All cardiovascular variables, blood glucose, haemoglobin and lactate concentrations were
analysed using different linear mixed effects models; the significance was set at p < 0.05. Results: S-
ketamine showed a two-compartment kinetic profile; no statistically significant differences were observed
between its concentrations or in the calculated pharmacokinetic parameters following S- or RS-ketamine.
When the racemic mixture was administered, no differences were detected between R- and S-ketamine
concentrations, but the area under the curve (AUC) for R-norketamine was significantly lower than
that for S-norketamine. Clinically relevant physiologic variables did not show statistically significant
differences following the administration of the racemic mixture or of S-ketamine alone. Conclusions and
clinical relevance: This study performed in dogs showed that RS-ketamine and S-ketamine combined with
medetomidine showed enantioselective pharmacokinetics as S- and R-norketamine AUCs were different,
but S-ketamine levels were identical.
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Abstract
Objective To assess the differences in the pharmacokinetic
profiles of S-ketamine, R-ketamine and their metabolites, S-
norketamine and R-norketamine, and to measure relevant
physiologic variables after intravenous administration of
racemic (RS) ketamine or S-ketamine alone in Beagle dogs
sedated with medetomidine.
Study design Experimental, blinded and randomized
crossover study.
Animals A total of six (three female and three male) adult
Beagle dogs.
Methods Medetomidine (450 mg me2) was administered
intramuscularly, followed by either S-ketamine (2 mg kge1)
or RS-ketamine (4 mg kge1) 20 minutes later, both
administered intravenously. Blood samples were collected
before medetomidine administration and at multiple time
points 1e900 minutes following the ketamine administra-
tion. Plasma samples were analysed using liquid
chromatographyetandem mass spectrometry. Heart rate,
respiratory rate, noninvasive blood pressure, haemoglobin
saturation with oxygen and body temperature were
measured at baseline, before ketamine administration, and
1, 2, 5, 10, 15, 20 and 30 minutes after ketamine
administration. All cardiovascular variables, blood glucose,
haemoglobin and lactate concentrations were analysed
using different linear mixed effects models; the significance
was set at p < 0.05.
Results S-ketamine showed a two-compartment kinetic
profile; no statistically significant differences were observed
between its concentrations or in the calculated
pharmacokinetic parameters following S- or RS-ketamine.
When the racemic mixture was administered, no differ-
ences were detected between R- and S-ketamine concen-
trations, but the area under the curve (AUC) for R-
norketamine was significantly lower than that for S-nor-
ketamine. Clinically relevant physiologic variables did not
show statistically significant differences following the
administration of the racemic mixture or of S-ketamine
alone.
Conclusions and clinical relevance This study performed in
dogs showed that RS-ketamine and S-ketamine combined
with medetomidine showed enantioselective pharmacoki-
netics as S- and R-norketamine AUCs were different, but S-
ketamine levels were identical.
Keywords canine, medetomidine, pharmacokinetics, S-
ketamine, S-norketamine.
Introduction
Ketamine is a dissociative anaesthetic, widely used in human
and veterinary anaesthesia. It is a racemic mixture of two
optical isomers, R- and S-ketamine, which have different
pharmacological effects (Bergman 1999). S-ketamine is
available for dogs in some European countries. In humans, the
relative potency of S-ketamine is twice that of the racemic (RS)
ketamine Q2, and the loss of response to verbal commands is seen
at half the dose of S-ketamine compared with RS-ketamine
(Ihmsen et al. 2001). In dogs and ponies, the clearance of S-
ketamine administered alone is higher than that of S-ketamine
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2001; Duque et al. 2008; Larenza et al. 2009). This explains
the faster recovery seen in patients anaesthetized with the S-
enantiomer alone (Ihmsen et al. 2001; Duque et al. 2008).
Clinically relevant physiologic functions are usually well
maintained with ketamine when in combination with mod-
erate doses of a2-adrenoceptor agonists. Studies in ponies and
horses (Filzek et al. 2003Q3 ; Larenza et al. 2007), however, have
shown some differences in the cardiopulmonary effects related
to the stereoselectivity of ketamine.
The combination of RS-ketamine with a2-adrenoceptor ag-
onists has been widely used in dogs to induce sedation and
anaesthesia (Ueyema et al. 2008). This drug combination
produces an adequate quality and duration of sedation and
anaesthesia for minor medical and surgical procedures. a2-
Adrenoceptor agonists alter the metabolism of other co-
administered drugs, such as opioids and ketamine in vitro,
mainly via an interaction with cytochrome P (CYP) enzymes
(Kharasch et al. 1991; Sandbaumhüter et al. 2015). This
interaction can influence the intensity and duration of the ef-
fects of ketamine.
The aims of this study were to obtain the pharmacokinetic
profiles of S-ketamine and R-ketamine, and their major me-
tabolites, S-norketamine and R-norketamine, in healthy Bea-
gles sedated with intramuscular (IM) medetomidine after
intravenous (IV) administration of RS-ketamine or S-ketamine.
Clinically relevant physiologic variables were also compared.
We hypothesized that the pharmacokinetics of ketamine’s
enantiomers and its metabolites, when combined with mede-
tomidine, were not stereoselective in dogs administered RS-
ketamine or the S-isoform alone.
Material and methods
Animals
The trial was approved by the committee for Animal Experi-
mentation of XXX 67/2011. A total of six healthy adult Beagle
dogs, three females and three males (non-castrated), aged 21 ±
11 [mean ± standard deviation (SD)] months of age and
weighing 15.0± 1.1 (mean ± SD) kg, were used in the study. A
post hoc power calculation on the pharmacokinetic dataQ4 was
used to verify the adequacy of the number of dogs included,
and the power was 99.5% for six dogs.
Complete blood cell count and blood chemistry were
assessed 2 days before the experiment. The dogs were fasted
overnight, but always had free access to water.
Drug administration and monitoring
This was a blinded, randomized crossover trial with a 3 week
washout period between treatments. A random order gener-
ator (GraphPad Software, CA, USA) determined treatment
allocation. The study was performed following good clinical
practice guidelines (Flecknell 1993).
Following standard aseptic preparation, two peripheral
venous catheters (Surflo IV Catheter 22 gauge, Terumo,
Belgium) were inserted into both the cephalic veins of each
dog, one catheter for drug administration and the other as a
reserve. An additional catheter was placed in the jugular vein
(16 gauge, 16 cm long, Blue Flex Tip Catheter, Arrow Inter-
national, Teleflex Medical GmbH, Switzerland) following infil-
tration of lidocaine (1 mL; Lidocain 2%, Streuli, Switzerland).
This catheter was used for central venous blood sampling. The
catheter for drug administration was attached to a lactated
Ringer infusion (Ringer-Lactat Fresenius; Fresenius Kabi AG,
Switzerland) at a rate of 5 mL kge1 houre1 for 30 minutes prior
to anaesthesia induction. The dogs were sedated with IM
medetomidine administered at a dose rate of 450 mg me2
(approximately 17 mg kge1 in a 15 kg dog, Dorbene, Fort
Dodge, Italy). After 20 minutes, S-ketamine 2 mg kge1 (Keta-S;
Dr. E. Graeub AG, Switzerland) (S-KET treatment) or RS-
ketamine 4 mg kge1 (Ketasol-100; Dr. E. Graeub AG) (RS-
KET treatment) were rapidly administered IV over 1e2
seconds.
Once anaesthesia was induced (identified by loss of laryngeal
reflex), the dogs were intubated and allowed to breath room air
(fraction of inspired oxygen ¼ 0.21). A multiparameter
monitor (BN 850, GE Medical Systems, Anandic Medical Sys-
tems AG, Switzerland) was used to monitor anaesthesia. The
following measurements were taken: heart rate (HR) from an
electrocardiogram, respiratory rate (fR), indirect arterial blood
pressures [systolic (SAP), mean (MAP) and diastolic (DAP)],
haemoglobin (Hb) saturation with oxygen in % (SpO2), end-
tidal carbon dioxide (PE0CO2) and body temperature (T
).
These variables were recorded at baseline [before medetomi-
dine administration ¼ time point (T-22)], at T-1 (20 minutes
after medetomidine injection and prior to ketamine adminis-
tration), and 1, 2, 5, 10, 15, 20 and 30 minutes after the
ketamine administration. Before ketamine administration, and
5 and 30 minutes after ketamine injection, blood glucose
(Contour, Bayer AG Heathcare, Switzerland), lactate (Accu-
trend, Roche Diagnostics, Switzerland) and Hb concentration
(Hemocue Hb201þ, Baumann Medical AG, Switzerland) were
measured.
The peripheral venous catheters were removed 30 minutes
after drug administration. The dogs were given 4 mg kge1 IV
carprofen (Rimadyl ad us. Vet, Pfizer AG, Switzerland) 4 hours
after drug administration. The dogs were observed by veteri-
narians and offered a commercial diet once they were fully
awake. During and after anaesthesia, the dogs’ body temper-
atures were maintained at 37.0e38.5 C using warm water
blankets (Hico-Aquatherm 660, Nufer Medical, Switzerland), a
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Systems AG) and a forced air-patient warming system (Bair
Hugger Model 505, Carbamed, Switzerland) as needed. After
taking the last blood
Q1
sample, the jugular catheter was
removed.
Sample collection
A blood sample was taken for determination of plasma drug
concentration 2 minutes before medetomidine administration
(T-22) and 20 minutes after (T-2), prior to anaesthesia in-
duction. Blood samples were also collected at anaesthesia in-
duction (T0), 1, 2, 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120,
150, 180, 210, 240, 300, 360, 450, 540, 630, 720, 810 and
900 minutes after ketamine administration. Samples for
determination of plasma drug levels were collected from the
central venous catheter and put into labelled heparinized tubes
(BD 3.5 mL Vacutainer, Becton Dickinson, Belgium). A total of
4 mL of blood were drawn before each sample and were re-
injected immediately after, and the catheter was then flushed
with 5 mL of saline (B-Braun, Melsungen, Germany). The
effective time of sampling was recorded for each sample.
Immediately after collection, the samples were centrifuged at 4
C and 3000 g for 10 minutes (Sarstedt LC 1-K, Germany). The
plasma was stored ate80 C in suitable tubes (Nunc 1.8 mL SI
Cryotube vials; Nunc A/S, Denmark) until analysis.
Plasma drug analysis
The plasma samples were analysed using the liquid chroma-
tography tandem mass spectrometry (LC-MS/MS) method,
previously described by Romagnoli et al. (2017). Briefly, after
the addition of labelled internal standards (Ketamine-d4 and
Norketamine-d4; Sigma-Aldrich, MO, USA), 150 mL of plasma
were extracted with methanol and centrifuged. The superna-
tant was filtered through a 0.2 mm PTFE filter (Phenomenex,
CA, USA) prior to analysis.
The LC system consisted of a Waters Aquity UPLC binary
pump (Waters, MA, USA), equipped with a Phenomenex Lux 3
mm Cellulose-3 (150  2.00 mm, 3.0 mmQ5 ) column (Phenom-
enex). The mobile phase was a mixture of acetonitrile and an
aqueous solution containing ammonium acetate 20 mM and
ammonium formate 0.1% at a flow rate of 0.45 mL minutese1
under programmed conditions. The LC was interfaced to a
Waters Quattro Premier XE triple quadrupole mass spectrom-
eter (Waters), operating in positive electrospray ionization, and
two specific transitions were observed for each analyte (Keta-
mine: 238/ 125 and 179 m/z, Norketamine: 224/ 125
and 207 m/z) and for each internal standard (Ketamine-D4:
242/ 129 and 183 m/z, Norketamine-D4: 228/ 129 and
211 m/z).
The analytical method was validated in accordance with
EMEA/CHMP/EWP/192217/2009 guidelines at the beginning
of the experiment. Linearity was satisfactory (R2 > 0.99) over a
range extending from 15 to 15,000 ng mLe1 for both S-keta-
mine and R-ketamine, and from 15 to 3000 ng mLe1 for the
norketamine enantiomers. The lower limit of quantification
was 15 ng mLe1 for all target compounds; interday and
intraday accuracy and precision were both below 10% for all
the analytes.
Pharmacokinetics and statistical analysis
The aim of the statistical analysis was to detect potential dif-
ferences in the repeated measurements of the cardiopulmonary
variables, Hb, lactate and glucose concentrations between the
two treatments. For each of the outcome variables, different
linear mixed effects models were run. In all models, dog was
included as a random intercept to account for potential clus-
tering within animals. In contrast, in the different models, time
was included either as a fixed effect, with or without an
interaction term with treatment, or as a random slope. The
treatments were included as a fixed effect and omitted in the
null model. Model selection was based on Akaike’s information
criterion (AIC) and on likelihood ratio tests which provided the
p values.
The analysis was carried out using R software (R Core Team
2018) and the packages: nlme (Pinheiro et al. 2018) and
lmtest (Zeileis & Hothorn 2002). Based on the assumption of
missing at random, the missing values were provided using the
package missForest (Stekhoven 2013). All cardiopulmonary
variables, Hb, lactate and glucose concentrations are reported
as mean ± SD.
The R-ketamine and S-ketamine concentration versus time
curves were analysed for each individual by XY plot using
WinNonlin 6.3 (Pharsight Corporation, CA, USA).
The plasma drug concentrations obtained after IV adminis-
tration were fitted using the following equation:
C(t) ¼ A eeat þ B eebt.
All pharmacokinetic parameters are reported as mean ± SD
and were determined using WinNonlin 6.3 (Pharsight Corpo-
ration). The individual plasma concentration versus time
curves were fitted, and the best compartment model was
determined by application of the AIC (Yamaoka et al. 1978).
The following pharmacokinetic parameters were calculated
for each dog for the ketamine enantiomers: area under the
curve to infinity (AUC0/∞), half-life of the distribution phase
(T1/2dis), half-life of the elimination phase (T1/2el), rate con-
stants of the elimination phase (Kel), mean residence time
(MRT), total body clearance (ClB), volume of distribution of the
central compartment (Vc), peak concentration (Cmax) and time
of peak concentration (Tmax). For S-norketamine and R-nor-
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the AUC 0/∞, Cmax and Tmax of metabolite concentration. The
Wilcoxon signed-rank test was used to detect differences be-
tween the treatments concerning the pharmacokinetic pa-
rameters with a significance level of p < 0.05.
Results
All the dogs enrolled in the study also finished the study and
recovered without any complications. The dogs came from the
pool of experimental dogs of the Vetsuisse Faculty of the Uni-
versity of Zürich, where they returned 24 hours after the end of
the study.
Sedation was considered to be profound following medeto-
midine administration, and S- and RS-ketamine were injected
according to the scheduled times. Intubation was judged to be
easy in four dogs in the RS-KET treatment and two dogs in the
S-KET treatment, and less easy but possible in the remaining
dogs. In the RS-KET treatment, one dog showed several epi-
sodes of muscle shaking 3.5 minutes following drug adminis-
tration. All dogs recovered well from the anaesthesia and were
standing within 37.9± 16.9 minutes and 42.9 ± 19.6 minutes
in S-KET and RS-KET treatments, respectively. No significant
difference was detected between treatments.
The cardiovascular variables are summarized in Table 1. The
SpO2 ranged between 98% and 100% in all dogs. Some car-
diopulmonary measurements were only possible when the
dogs were unconscious and tolerated the endotracheal tube
(e.g., PE0CO2) or other measurement devices.
No significant treatment effect was detected in the following
variables: HR (p ¼ 0.068), fR (p ¼ 0.388), SAP (p ¼ 0.465),
DAP (p ¼ 0.260), MAP (p ¼ 0.355), T (p ¼ 0.317), SpO2 (p ¼
0.967), Hb (p ¼ 0.09), lactate (p ¼ 0.230) and glucose (p ¼
0.185).
Plasma drug concentrations
Due to technical problems with the drug assay, the concen-
trations of R- and S-enantiomers from the racemic mixture
could not be determined in one dog.
The plasma drug concentrations of both the ketamine and
norketamine enantiomers were plotted against the time points
for both RS-ketamine and S-ketamine administration (Figs. 1&
2). No statistically significant differences were detected be-
tween the concentrations of S-ketamine alone, and R-ketamine
and S-ketamine after administration of the racemic mixture, at
any time. Neither R-ketamine nor R-norketamine were
detected after the administration of S-ketamine.
Pharmacokinetic parameters
The S-ketamine plasma concentration following the IV
administration of a bolus of RS-ketamine or S-ketamine alone
Table 1 Mean ± standard deviation values of heart rate (HR), systolic (SAP), diastolic (DAP), mean arterial pressure (MAP), respiratory rate
(fR), end-tidal carbon dioxide (PE
0CO2), glucose, lactate plasma concentrations and haemoglobin (Hb) in six Beagle dogs. The dogs were sedated
with medetomidine (450 mg me2) and given a bolus of S-ketamine [S-KET (2 mg kge1)] or racemic ketamine [RS-KET (4 mg kge1)] 20
minutes after medetomidine administration (T0)
Time (minutes) Treatment Baseline 0 1 2 5 10 15 20 30
HR (beats minutee1) S-KET 103 ± 16 48 ± 3 82 ± 16 82 ± 21 84 ± 8 75 ± 19 68 ± 21 60 ± 7 58 ± 18
RS-KET 108 ± 19 53 ± 9 100 ± 9 108 ± 23 86 ± 9 74 ± 7 60 ± 7 54 ± 5 54 ± 5
SAP (mmHg) S-KET 197 ± 0 197 ± 40 151 ± 25 133 ± 36 145 ± 46 137 ± 35 147 ± 5
RS-KET 154 ± 45 162 ± 38 153 ± 26 159 ± 27 158 ± 21 141 ± 13
DAP (mmHg) S-KET 137 ± 0 118 ± 42 98 ± 30 84 ± 23 81 ± 23 86 ± 27 10 ± 8
RS-KET 97 ± 43 96 ± 24 96 ± 33 96 ± 24 99 ± 23 82 ± 21
MAP (mmHg) S-KET 161 ± 0 144 ± 40 120 ± 29 102 ± 29 107 ± 33 107 ± 29 121 ± 5
RS-KET 116 ± 39 126 ± 34 117 ± 30 120 ± 23 122 ± 20 105 ± 17
fR (breaths minute
e1) S-KET 28 ± 5 19 ± 5 8 ± 7 9 ± 6 10 ± 6 17 ± 7 22 ± 7 23 ± 4 24 ± 9
RS-KET 25 ± 7 20 ± 6 13 ± 12 8 ± 8 7 ± 4 12 ± 5 23 ± 20 23 ± 8 28 ± 6
PE0CO2 (kPa) S-KET 4.4 ± 1.3 6.3 ± 0.3 5.6 ± 1.9
RS-KET 5.8 ± 1.5 7.0 ± 0.4 6.6 ± 0.6 6.1 ± 0.0
PE0CO2 (mmHg) S-KET 33.0 ± 9.9 47.6 ± 2.3 42.0 ± 14.2
RS-KET 43.3 ± 11.0 52.2 ± 3.0 49.3 ± 4.2 46.0 ± 0.0
Glucose (mmol Le1) S-KET 4.2 ± 0.4 4.5 ± 0.7 4.7 ±1.0
RS-KET 4.6 ± 0.8 4.3 ± 0.7 4.6 ± 0.7
Lactate (mmol Le1) S-KET 5.4 ± 3.7 2.3 ± 0.5 2.0 ± 1.1
RS-KET 2.4 ± 1.1 1.8 ± 0.9 2.5 ± 0.3
Hb (g dLe1) S-KET 14.4 ± 1.2 13.4 ± 1.5 11.9* ± 1.2
RS-KET 13.6 ± 1.9 13.8 ± 1.0 13.7 ± 0.9
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was best described using a two-compartment model. The
pharmacokinetic parameters are summarized in Table 2. No
statistically significant differences were observed in S-enan-
tiomer concentrations between treatments. Furthermore,
there was no significant difference between two enantiomers in
the RS-KET treatment. The AUC0/∞ for S-norketamine, after
both RS-ketamine and S-ketamine administration, was signif-
icantly higher than that for R-norketamine measured after
injection of the racemic mixture.
Discussion
In this study, following IM administration of medetomidine, the
pharmacokinetic parameters of S-ketamine after a single IV
injection of the racemic drug or the S-enantiomer alone did not
differ significantly from one another. In addition, the phar-
macokinetic results for the R-isomer did not differ significantly
from those of S-ketamine after RS-ketamine administration
either.
The cardiovascular and respiratory effects observed
following medetomidine and ketamine administration are in
accordance with those previously reported for protocols
including ketamine and medetomidine (Ko et al. 2001; Enouri
et al. 2008). a2-Adrenoceptor agonist administration
commonly causes bradycardia, as observed in our study. This
results from both an increase in systemic vascular resistance
and a decrease in sympathetic tone (Pypendop & Verstegen
1998). In the present study, it was not possible to evaluate
the noninvasive blood pressure before RS-ketamine or S-keta-
mine administration due to the temperament of the dogs.
However, the administration of both the RS-ketamine and S-
ketamine induced an increase in HR, as previously reported in
dogs by Enouri et al. (2008). In the present study, the car-
diovascular effects of the two different anaesthetic protocols
Figure 1 Mean plasma concentrations (error bars represent standard deviation) of R-ketamine (R-ket) and S-ketamine (S-ket) for the RS-KET
treatment graph (a) and S-ketamine (S-ket) for the S-KET treatment graph (b) after the administration of racemic ketamine 4 mg kge1 or S-
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were comparable, as were the recovery times. In human vol-
unteers sedated with midazolam, S-ketamine provided faster
recovery than RS-ketamine administered at twice the dose of S-
ketamine alone (Doenicke et al. 1992).
In the present study, concentration of S-norketamine was
significantly more than that of R-norketamine in plasma.
These findings disagree with those reported by Sandbaumhüter
et al. (2016); they did not find any statistically significant dif-
ferences between the two enantiomers in Beagle dogs. More-
over, lower overall S-norketamine and R-norketamine
concentrations were observed in the dogs included in the
present study than dogs anaesthetized with sevoflurane
(Romagnoli et al. 2017). Mechanical ventilation and sevo-
flurane may influence cardiovascular function and thus drug
disposition and elimination (Romagnoli et al. 2017). In the
present study, all the dogs were sedated with medetomidine,
which also has an influence on the ketamine metabolism
(Kharasch et al. 1992; Sandbaumhüter et al. 2016). Such
variation might be related to a reduction of the cardiac output
(CO). In a previous study, Pypendop & Verstegen (1998) re-
ported that medetomidine administered to healthy dogs
significantly reduced CO and may thereby reduce hepatic
perfusion. Conversely, Lawrence et al. (1996) reported that
dexmedetomidine, the active enantiomer of medetomidine,
decreased renal blood flow by 25% but did not affect liver blood
flow. Furthermore, Restitutti et al. (2013), observed that
dexmedetomidine induced changes in the blood flow of the
abdominal organs, especially in the kidneys. In the study re-
ported by Sandbaumhüter et al. (2016), no significant differ-
ences were detected in the metabolic profile of ketamine of
urine when dogs were administered either sevoflurane or
medetomidine. Therefore, it seemed likely that both medeto-
midine and sevoflurane could decrease ketamine elimination.
The hepatic metabolism of both ketamine and medetomidine is
Figure 2 Mean plasma concentrations (error bars represent standard deviation) of R-norketamine (R-nor) and S-norketamine (S-nor) in the RS-
KET treatment graph (a) and S-norketamine (S-nor) in the S-KET treatment graph (b) after the administration of racemic ketamine 4 mg kge1 or
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catalysed by CYP3A4 and orthologs of CYP2C9 enzymes
(Capponi et al. 2009; Schmitz et al. 2010), and they have also
shown an elevated affinity for medetomidine in dogs (Duhamel
et al. 2010). a2-Adrenoceptor agonists inhibit CYP450 by
means of their imidazole ring which binds to the haem iron of
CYP (Sandbaumhüter et al. 2015) and they, therefore, slow
the metabolism of drugs which use the same enzymatic
pathway as demonstrated in vitro.
In this study, neither the Vc nor ClB of S-ketamine and R-
ketamine differed significantly from one another in dogs
administered RS-ketamine; nor did these parameters differ
when the values of S-ketamine were compared to RS-
ketamine. Our findings were in accordance with those previ-
ously reported in dogs anaesthetized with sevoflurane and
given RS-ketamine or the S-isomer (Romagnoli et al. 2017).
They suggest the absence of stereoselectivity in the distribution
and clearance of ketamine enantiomers in dogs sedated with
medetomidine. Similar results have previously been obtained
in ponies receiving RS-ketamine or S-ketamine and anaes-
thetized with isoflurane or sedated with xylazine (Larenza et al.
2007; 2008).
Lower AUC0/∞ and Cmax for R-norketamine compared to S-
norketamine have already been reported in ponies anaes-
thetized with isoflurane or xylazine (Larenza et al. 2007,
2008). Some authors have hypothesized the existence of dif-
ferences in protein binding between the two enantiomers
which could have influenced their renal clearance (Larenza
et al. 2007). A previous in vitro study has demonstrated that
the co-administration of medetomidine and RS-ketamine pro-
duced a stronger inhibition of the formation of R-norketamine
than S-norketamine (Sandbaumhüter et al. 2015). In the
present study, we hypothesized that medetomidine inhibited
RS-ketamine demethylation to R-norketamine in preference
for S-norketamine. Since norketamine metabolites were not
evaluated, the preference of pharmacologically inactive R-
norketamine over the active S-norketamine hydroxylation
cannot be excluded. However, the pharmacokinetics of 6-
hydroxynorketamine and dehydronorketamine enantiomers
have already been determined in dogs sedated with medeto-
midine (Sandbaumhüter et al. 2016). In that study, a higher
Cmax of (2R,6R)-6-hydroxynorketamine compared with
(2S,6S)-6-hydroxynorketamine was observed after adminis-
tration of the racemic mixture; similar results were not found
for 5,6-dehydronorketamine. In the study of Sandbaumhüter
et al. (2016), there were no differences between R- and S-
norketamine pharmacokinetics. However, in the present study,
inhibition of the formation of the R-isoform over the S-isoform
of norketamine was observed following medetomidine admin-
istration. In canine clinical practice, the pharmacological effect
of ketamine metabolites, particularly S-norketamine, is still
unclear. However, an analgesic effect similar to that of RS-
ketamine was reported for this metabolite in a rodent model
(Holtman et al. 2008). In the present study, no analgesic
evaluations were performed in Beagle dogs.
Both dexmedetomidine and levomedetomidine are potent
in vitro inhibitors of the N-demethylation of S- and R-ketamine
to norketamine (Kharasch et al. 1992). Hence, racemic
medetomidine was expected by the author of the present study
to be a more potent inhibitor than dexmedetomidine alone.
Additional studies are needed to evaluate the effects of
Table 2 Mean values ± standard deviation of the pharmacokinetic parameters of ketamine and norketamine enantiomers in plasma samples
obtained from five dogs sedated with medetomidine and an intravenous bolus of S-ketamine (S-KET) or racemic ketamine (RS-KET) (refer to
Table 1 for drugs doses administered)
Treatment S-KET RS-KET
Compound S-ketamine S-ketamine R-ketamine
AUC0/∞ (mg minutes mL
e1) 37.21 ± 5.28 36.83 ± 13.00 35.58 ± 12.15
T1/2dis (minutes) 2.47 ± 1.09 2.44 ± 1.39 2.52 ± 1.35
T1/2el (minutes) 43.77 ± 20.12 46.02 ± 18.51 46.74 ± 18.08
Kel (1 minute
-1) 0.02 ± 0.01 0.02 ± 0.02 0.02 ± 0.01
MRT (minutes) 45.00 ± 20.23 45.25 ± 16.00 46.39 ± 15.38
ClB (mL minute
e1 kge1) 54.62 ± 7.73 59.82 ± 20.94 61.78 ± 21.76
Vc (L kg
e1) 1.79 ± 0.69 1.94 ± 0.52 2.03 ± 0.57
S-norketamine S-norketamine R-norketamine
AUC0/∞ (mg*minutes mL
e1) 3.27 ± 0.94* 3.29 ± 0.86y 1.45 ± 0.25*y,
Cmax (mg mL
e1) 0.05 ± 0.01 0.05 ± 0.01 0.04 ± 0.01
Tmax (minutes) 6.00 ± 2.24 7.40 ± 5.13 8.40 ± 6.14
AUC0-∞, Area under the curve to infinity; T½dis, half-life of the distribution phase; T½el, half-life of the elimination phase; Kel, rate constants of the elimination phase; MRT, mean
residence time; ClB, body clearance; Vc, volume of distribution for the central compartment; Cmax, peak concentration; Tmax, time of peak concentration. *Significant difference
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dexmedetomidine on ketamine and norketamine disposition,
and pharmacokinetics with respect to medetomidine.
This study has some limitations; there was a high intra- and
inter-individual variability of cardiorespiratory variables. In
addition, some dogs did not tolerate monitoring devices being
attached while awake; thus, some measurements before and
after sedation and anaesthesia were not performed. As the
variability was higher than expected, the study was under-
powered with regards to cardiorespiratory measurements and,
therefore, could not detect whether there were any differences
between treatments. Moreover, the exclusion of one dog from
the statistical analysis could result in a low statistical power,
thereby increasing the risk of beta error.
Conclusions
This study confirmed that the distribution and clearance of
ketamine enantiomers, when combined with medetomidine,
were not stereoselective in dogs administered RS-ketamine or
the S-isoform alone. However, the metabolism of ketamine was
inhibited, as demonstrated by low norketamine concentrations
with R-norketamine being the most affected. Despite these
differences in metabolite disposition, no significant differences
between the two treatments were observed regarding the
cardiopulmonary variables studied.
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